| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.47 | 0.02 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |